Breckenridge Pharmaceutical, Inc.,a privately-held pharmaceutical marketing, research and development company, has launched rizatriptan benzoate tablets. The US Food and Drug Administration (FDA) granted final approval for the Abbreviated New Drug Application (ANDA) for this product, which is being manufactured and supplied by Natco Pharma Limited, and will be available in both 5mg and 10mg strengths.
Rizatriptan benzoate tablets are AB rated to Maxalt, a $320 million dollar brand drug marketed by Merck. Maxalt is a prescription medicine indicated for the acute treatment of migraines.
Breckenridge is a privately-held pharmaceutical marketing, research and development company that markets a broad range of generic prescription products and Medical Foods in many therapeutic categories.